CERVCO is the French National Reference Centre for Rare Cerebrovascular and Retinal Diseases, accredited by the Ministry of Health since 2005. Since 2017, CERVCO has coordinated the MRVC cohort, a prospective cohort of patients with rare vascular diseases of the brain and retina, and established the associated B-MRVC biobank in 2020 to support translational research and biomarker discovery.
Due to the rarity and heterogeneity of these disorders, centralized longitudinal collection of clinical data and biological samples is essential to improve understanding of disease mechanisms, identify biomarkers of progression and prognosis, and facilitate the development of new diagnostic and therapeutic approaches.
The present study aims to expand this longitudinal biobank, enable national and international collaborative research through controlled sample sharing, and establish reference control samples to support biomarker validation.
Patients aged between 18 and 80 years at the time of inclusion
Diagnosis confirmed by the detection of a pathogenic mutation in the NOTCH3 gene characteristic of CADASIL, or in another gene responsible for other forms of monogenic cSVD (such as the COL4A1, COL4A2 and HTRA1 genes) or a confirmed diagnosis of MOYA-MOYA (arteriography and/or genetic testing) or cavernoma, cerebral venous thrombosis or a cerebral vascular malformation, including cavernomas
Covered by social security or an equivalent scheme
Written consent.
Pregnant women, women in labour or breastfeeding women
Persons deprived of their liberty by judicial or administrative decision
Persons hospitalised without consent and not subject to a legal protection measure, and persons admitted to a health or social care facility for purposes other than research
Minors
Parallel
Biocollection
Other interventionAdditional blood collection
Neurological evaluation and Biocollection
Other interventionFor healthy volunteers: neurological evaluation, blood and urine sampling
Comparative analysis of proteins
Comparative analysis of proteins and candidate biomarkers in serum or plasma between patients with a rare brain disorder and control subjects
Measurement of proteins and biomarkers
Occurrence of a significant event indicating disease progression
Stroke, cognitive decline, progressive markers in brain or retinal imaging
Inter-method variability of assays assessed by measures of agreement between techniques
Protein/biomarker assays according to the different conditions involved
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
